SCHEMBL3452192

SCHEMBL3452192

Clc1ccnc(NCc2cccs2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 12/20 0.56
CYP2D6 P10635 12/20 0.56
ALDH1A1 P00352 11/20 0.56
CYP3A4 P08684 11/20 0.56
CYP2C19 P33261 11/20 0.56
TSHR P16473 8/20 0.56
MAPK1 P28482 6/20 0.56
LMNA P02545 5/20 0.56
CLK4 Q9HAZ1 7/20 0.51
MEN1 O00255 6/20 0.51
KMT2A Q03164 6/20 0.51
ALOX15 P16050 4/20 0.51
HSD17B10 Q99714 4/20 0.51
USP2 O75604 3/20 0.51
KCNN1 Q92952 1/20 0.51
KCNN2 Q9H2S1 1/20 0.51
KCNN3 Q9UGI6 1/20 0.51
GBA1 P04062 2/20 0.50
CYP2C9 P11712 1/20 0.50
KCNH3 Q9ULD8 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27909931 0.81 HDAC3 (0.58) CYP1A2CYP2D6ALDH1A1CYP3A4CYP2C19
SCHEMBL3452402 0.80 CYP1A2 (0.66) CYP1A2CYP2D6ALDH1A1CYP3A4CYP2C19
SCHEMBL3451695 0.74 ALDH1A1 (0.50) CYP1A2CYP2D6ALDH1A1CYP3A4CYP2C19
SCHEMBL1935183 0.74 MEN1 (0.38) CYP1A2CYP2D6ALDH1A1CYP3A4CYP2C19
SCHEMBL29836535 0.73 ATM (0.55) CYP1A2CYP2D6ALDH1A1CYP3A4CYP2C19
SCHEMBL10441707 0.73 ATM (0.55) CYP1A2CYP2D6ALDH1A1CYP3A4CYP2C19
SCHEMBL5940015 0.71 HDAC3 (0.55) CYP1A2CYP2D6ALDH1A1CYP3A4CYP2C19
SCHEMBL3976219 0.71 MAOA (0.54) ALDH1A1TSHRLMNAMEN1KMT2A
SCHEMBL2719597 0.71 TSHR (0.49) CYP1A2CYP2D6ALDH1A1CYP3A4CYP2C19
SCHEMBL23093434 0.71 ALDH1A1 (0.49) CYP1A2CYP2D6ALDH1A1CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820704-B2 Substituted heteroaryl derivatives, compositions, and methods of use TRANSTECH PHARMA, INC. (US) 2010-10-26 US disclosed
EP-1753735-A1 SUBSTITUTED THIAZOLE AND PYRIMIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR MODULATORS Transtech Pharma, Inc. (US) 2007-02-21 EP disclosed
US-20050261294-A1 Substituted heteroaryl derivatives, compositions, and methods of use VTVX HOLDINGS I LLC 2005-11-24 US disclosed
WO-2005103022-A1 SUBSTITUTED THIAZOLE AND PYRIMIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR MODULATORS TRANSTECH PHARMA, INC. (US) 2005-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261294-A1 Substituted heteroaryl derivatives, compositions, and methods of use MC5R, MC3R, MC4R CYP1A2 261/4885CYP2D6 328/4885ALDH1A1 1513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.